Drug Patents owned by Tris Pharma Inc

1. List of Dyanavel Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675703 TRIS PHARMA INC Modified release formulations containing drug - ion exchange resin complexes
Mar, 2027

(3 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(3 years from now)

US8597684 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(3 years from now)

US8883217 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(3 years from now)

US10086087 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(3 years from now)

US8062667 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(6 years from now)

US11590228 TRIS PHARMA INC NA
Sep, 2036

(13 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: Method of treating attention deficit hyperactivity disorder

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR family patents

25

United States

2

Denmark

2

Spain

2

China

2

European Union

1

Israel

1

Russia

1

Japan

1

Brazil

1

Austria

1

Canada

1

Australia

1

Korea, Republic of

1

Taiwan, Province of China

2. List of Dyanavel Xr 10 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(3 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(3 years from now)

US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(3 years from now)

US11590081 TRIS PHARMA INC NA
Sep, 2038

(15 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: Method of treating attention deficit hyperactivity disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR 10 family patents

25

United States

2

Denmark

2

Spain

2

China

2

European Union

1

Israel

1

Russia

1

Japan

1

Brazil

1

Austria

1

Canada

1

Australia

1

Korea, Republic of

1

Taiwan, Province of China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in